Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints [MarketWatch]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: MarketWatch
Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints Shares of Aldeyra Therapeutics Inc. ALDX, +68.07% shot up 56% toward a 5-month high in premarket trade Tuesday, a day after closing at a 7-month low, after a phase 3 trial of the biotechnology company's allergic conjunctivitis treatment met its primary and secondary endpoints. Trading volume topped 440,000 shares, already more than the full-day average of about 310,000 shares. Aldeyra said it plans to meet with regulatory authorities in the second half of 2019 to discuss the results and remaining clinical requirements for potential submission of a new drug application (NDA) to the Food and Drug Administration. Separately, the company said it entered into a loan and security agreement with Hercules Capital Inc. that provides up to $60 million in financing. "The ALLEVIATE [trial] results suggest the potential of topical ocular reproxalap as a novel, safe, and effective therapeutic option that co
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024Business Wire
- Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $10.00 price target on the stock.MarketBeat
- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
ALDX
Earnings
- 8/3/23 - Beat
ALDX
Sec Filings
- 4/17/24 - Form 4/A
- 4/17/24 - Form 4/A
- 4/8/24 - Form 4
- ALDX's page on the SEC website